Maravai LifeSciences Holdings Inc. Class A Common Stock vs Super Micro Computer Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Super Micro Computer Inc trades at $35.04 (market cap $25.67B). The key difference: Super Micro Computer Inc is far larger — about 26.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Super Micro Computer Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Super Micro Computer Inc for 20 Days on average.
| MRVI | SMCI | |
|---|---|---|
Market Cap | $972.90M | $25.67B |
Volume | 4,325,710 | 24,555,322 |
Sector | Health | Technology |
52-Week High | $9.00 | $55.04 |
52-Week Low | $2.83 | $20.53 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $1.08B | $31.13B |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Super Micro Computer (SMCI) trades at $39.07, down 2.28% today, with a bullish technical signal and strong fundamental growth. The stock shows robust earnings beats, with Q2 2026 EPS of $1.70 exceeding the $0.923 estimate, and revenue is projected to grow from $22.0B in 2025 to $39.1B in 2026. Analyst consensus is a $42.33 price target, with 36% buy ratings. Recent news highlights AI-driven order surges and new NVIDIA Vera Rubin shipments, supporting positive sentiment amid competitive pressures.
The outlook for SMCI is positive, driven by AI infrastructure demand and earnings momentum, but risks include margin pressure and a Department of Justice investigation. Valuation remains attractive with a P/E of 11.98, though debt levels and market volatility warrant caution. Upside potential exists if the company maintains its growth trajectory and navigates legal challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →